Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Doxorubicin is a commonly used chemotherapeutic agent for the treatment of a range of cancers, but despite its success in improving cancer survival rates, doxorubicin is cardiotoxic and can lead to congestive heart failure. Therapeutic options for this patient group are limited to standard heart failure medications with the only drug specific for doxorubicin cardiotoxicity to reach FDA approval being dexrazoxane, an iron-chelating agent targeting oxidative stress. However, dexrazoxane has failed to live up to its expectations from preclinical studies while also bringing up concerns about its safety. Despite decades of research, the molecular mechanisms of doxorubicin cardiotoxicity are still poorly understood and oxidative stress is no longer considered to be the sole evil. Mitochondrial impairment, increased apoptosis, dysregulated autophagy and increased fibrosis have also been shown to be crucial players in doxorubicin cardiotoxicity. These cellular processes are all linked by one highly conserved intracellular kinase: adenosine monophosphate–activated protein kinase (AMPK). AMPK regulates mitochondrial biogenesis via PGC1α signalling, increases oxidative mitochondrial metabolism, decreases apoptosis through inhibition of mTOR signalling, increases autophagy through ULK1 and decreases fibrosis through inhibition of TGFβ signalling. AMPK therefore sits at the control point of many mechanisms shown to be involved in doxorubicin cardiotoxicity and cardiac AMPK signalling itself has been shown to be impaired by doxorubicin. In this review, we introduce different agents known to activate AMPK (metformin, statins, resveratrol, thiazolidinediones, AICAR, specific AMPK activators) as well as exercise and dietary restriction, and we discuss the existing evidence for their potential role in cardioprotection from doxorubicin cardiotoxicity.
Beral V, Peto R. UK cancer survival statistics [Internet]. BMJ. 2010 [cited 2019 Nov 11]. p. 309. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk
Cancer Research UK. Breast cancer survival statistics [Internet]. 2005-2009. 2014 [cited 2019 Nov 11]. p. 1–5. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/survival/breast-cancer-survival-statistics
von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–7. CrossRef
Meiners B, Shenoy C, Zordoky BN. Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity. Biol Sex Differ. BioMed Central Ltd. 2018;9:38. CrossRef
Ansari L, Shiehzadeh F, Taherzadeh Z, Nikoofal-Sahlabadi S, Momtazi-Borojeni AA, Sahebkar A, et al. The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: A systematic review of clinical trials. Cancer Gene Ther. 2017;24:189–93. PubMedCrossRefPubMedCentral
Štěrba M, Popelová O, Vávrová A, Jirkovský E, Kovaříková P, Geršl V, et al. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxidants Redox Signal. 2013;18:899–929. CrossRef
Angsutararux P, Luanpitpong S, Issaragrisil S. Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress. Oxid Med Cell Longev. Hindawi Publishing Corporation; 2015;2015:1–13.
Lipshultz SE, Franco VI, Sallan SE, Adamson PC, K. Steiner R, Swain SM, et al. Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence. Prog Pediatr Cardiol. 2014;36:39–49. CrossRef
Varga Z V., Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol [Internet]. American Physiological Society; 2015;309:H1453–H1467. Available from: http://ajpheart.physiology.org/lookup/doi/10.1152/ajpheart.00554.2015 PubMedPubMedCentralCrossRef
Hardie DG, Carling D, Sim A TR. The AMP-activated protein kinase: a multisubstrate regulator of lipid metabolism. Trends Biochem Sci. 1989;14:20–23.
Suzuki A, Okamoto S, Lee S, Saito K, Shiuchi T, Minokoshi Y. Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the 2 form of AMP-activated protein kinase. Mol Cell Biol. 2007;27:4317–27. PubMedPubMedCentralCrossRef
Davies SP, Helps NR, Cohen PTW, Hardie DG. 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2Cα and native bovine protein phosphatase-2AC. FEBS Lett. 1995;377:421–5. PubMedCrossRef
Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: Possible roles in Type 2 diabetes. Am J Physiol – Endocrinol Metab. 1999;277:40–1. CrossRef
Lu Q, Li X, Liu J, Sun X, Rousselle T, Ren D, et al. AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases. Biosci Rep. 2019;39:1–15.
Li X, Liu J, Lu Q, Ren D, Sun X, Rousselle T, et al. AMPK: A therapeutic target of heart failure—not only metabolism regulation. Biosci Rep. Portland Press Ltd; 2019;39.
Li Y, Wang Y, Zou M, Chen C, Chen Y, Xue R, et al. AMPK blunts chronic heart failure by inhibiting autophagy. Biosci Rep. 2018;38.
Tokarska-Schlattner M, Zaugg M, Da Silva R, Lucchinetti E, Schaub MC, Wallimann T, et al. Acute toxicity of doxorubicin on isolated perfused heart: Response of kinases regulating energy supply. Am J Physiol - Hear Circ Physiol. 2005;289.
Yang W, Park IJ, Yun H, Im DU, Ock S, Kim J, et al. AMP-activated protein kinase α2 and E2F1 transcription factor mediate doxorubicin-induced cytotoxicity by forming a positive signal loop in mouse embryonic fibroblasts and non-carcinoma cells. J Biol Chem. 2014;289:4839–52. PubMedPubMedCentralCrossRef
Pointon AV, Walker TM, Phillips KM, Luo J, Riley J, Zhang SD, et al. Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation. PLoS One. 2010;5:1–17. CrossRef
Li R, Huang Y, Semple I, Kim M, Zhang Z, Lee JH. Cardioprotective roles of sestrin 1 and sestrin 2 against doxorubicin cardiotoxicity. Am J Physiol - Hear Circ Physiol. 2019;317:H39–48. CrossRef
Merrill GF, Kurth EJ, Hardie DG, Winder WW. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol - Endocrinol Metab. 1997;273.
Barreto-Torres G, Hernandez JS, Jang S, Rodríguez-Muñoz AR, Torres-Ramos CA, Basnakian AG, et al. The beneficial effects of amp kinase activation against oxidative stress are associated with prevention of PPARα-cyclophilin D interaction in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2015;308:749–58. CrossRef
Hyoung CC, Song P, Xie Z, Wu Y, Xu J, Zhang M, et al. Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo. J Biol Chem. 2008;283:20186–97. CrossRef
Huelsenbeck J, Henninger C, Schad A, Lackner KJ, Kaina B, Fritz G. Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death Dis. 2011;2. CrossRef
Henninger C, Huelsenbeck S, Wenzel P, Brand M, Huelsenbeck J, Schad A, et al. Chronic heart damage following doxorubicin treatment is alleviated by lovastatin. Pharmacol Res. 2015;91:1–10. CrossRef
Svvs R, Trivedi PP, Kushwaha S, Vikram A, Jena GB. Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice. J Physiol Biochem. 2013;69:513–25. CrossRef
Block G, Jensen CD, Norkus EP, Dalvi TB, Wong LG, McManus JF, et al. Usage patterns, health, and nutritional status of long-term multiple dietary supplement users: A cross-sectional study. Nutr J. 2007;6.
Zordoky BNM, Robertson IM, Dyck JRB. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta - Mol Basis Dis. 1852;2014:1155–77.
Dyck GJB, Raj P, Zieroth S, Dyck JRB, Ezekowitz JA. The effects of resveratrol in patients with cardiovascular disease and heart failure: A narrative review. Int J Mol Sci. 2019;20.
Sung MM, Das SK, Levasseur J, Byrne NJ, Fung D, Kim TT, et al. Resveratrol treatment of mice with pressure-overloadinduced heart failure improves diastolic function and cardiac energy metabolism. Circ Hear Fail. 2015;8:128–37. CrossRef
Kukidome D, Nishikawa T, Sonoda K, Imoto K, Fujisawa K, Yano M, et al. Activation of AMP-activated protein kinase reduces hyperglycemia induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes. 2006;55:120–7. PubMedCrossRef
Moussa A, Li J. AMPK in myocardial infarction and diabetes: the yin/yang effect. Acta Pharm Sin B. 2012;2:368–78. CrossRef
Hall SE, Smuder AJ, Hayward R. Effects of calorie restriction and voluntary exercise on doxorubicin-induced cardiotoxicity. Integr Cancer Ther. 2019;18. CrossRef
Kawaguchi T, Takemura G, Kanamori H, Tsujimoto A, Goto K, Ogino A, et al. Abstract 10979: Impairment of autophagic flux in doxorubicin cardiotoxicity and its restoration and improvement of cardiac function by prior starvation. Circulation [Internet]. 2012;126:A10979-. Available from: http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A10979
Timmermans AD, Balteau M, Gélinas R, Renguet E, Ginion A, de Meester C, et al. A-769662 potentiates the effect of other AMP-activated protein kinase activators on cardiac glucose uptake. Am J Physiol Heart Circ Physiol. 2014;306.
Zheng B, Peng Y, Wu W, Ma J, Zhang Y, Guo Y, et al. Synthesis and structure–activity relationships of pyrazolo-[3,4-b]pyridine derivatives as adenosine 5’-monophosphate-activated protein kinase activators. Arch Pharm (Weinheim). 2019;352.
Tyszka-Czochara M, Konieczny P, Majka M. Recent advances in the role of AMP-activated protein kinase in metabolic reprogramming of metastatic cancer cells: targeting cellular bioenergetics and biosynthetic pathways for anti-tumor treatment. J Physiol Pharmacol. 2018;69.
Marinello PC, Panis C, Silva TNX, Binato R, Abdelhay E, Rodrigues JA, et al. Metformin prevention of doxorubicin resistance in MCF-7 and MDAMB- 231 involves oxidative stress generation and modulation of cell adaptation genes. Sci Rep. 2019;9.
Van Den Neste E, Cazin B, Janssens A, González-Barca E, Terol MJ, Levy V, et al. Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): A multicenter phase I/II study. Cancer Chemother Pharmacol. 2013;71:581–91. CrossRef
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
Kerstin N. Timm
Damian J. Tyler
- Springer US
Cardiovascular Drugs and Therapy
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
Neu im Fachgebiet Kardiologie
Mail Icon II